Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide added to neoadjuvant chemotherapy for triple-negative breast cancer
IRCT20250927067373N1Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in triple-negative breast cancer (TNBC) comparing Lenalidomide plus neoadjuvant chemotherapy with Placebo plus neoadjuvant chemotherapy (2 arms). Primary endpoints: Pathologic response to neoadjuvant therapy, Efficacy and 2 more. Started Oct 2025; status: completed.
02
Drugs
lenalidomide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on IRCT20250927067373N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250927067373N1.